Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-... Academic Article uri icon


  • Human tropomyosin-related kinase (TRK) is a receptor tyrosine kinase family of neurotrophin receptors. Three isoforms of TRK have been described, TRKA, TRKB, and TRKC, which are encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. These genes are prone to rearrangements, which place them adjacent to active genes such as ETV6, EML4, NPM, and TPM. The resulting fusion proteins exhibit transformative oncogenic potential. Targeting the TRK family of receptors has shown promising evidence of providing clinical benefit to patients with TRK fusion cancers. 1, 2 Larotrectinib is a highly selective and potent inhibitor of the TRKs that in 2016 was awarded breakthrough designation by the US Food and Drug Administration on the basis of its promising early preclinical and clinical data in adults and children with tumors harboring TRK fusions. As reported by Hyman et …

publication date

  • June 1, 2018